Vaso-Occlusive Crisis clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for

  • Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

    open to eligible people ages 12 years and up

    This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

    Orange, California and other locations

  • Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

    Sorry, in progress, not accepting new patients

    This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.

    Orange, California and other locations

Last updated: